Infantile Haemangiomas
Conditions
Brief summary
This is retrospective study. The patients treated with oral propranolol at a dose of 2.0 mg/kg per day. Growth parameters (height and weight) were measured at the beginning, the end of treatment and 2 years after treatment. The weight-for-age Z-score (WAZ), height-for-age Z-score (HAZ) and weight-for-height Z-score (WHZ) calculated by the WHO Anthro software were used to assess physical development, and the WHO Child Growth Standards were used as the standards.
Interventions
DRUGpropranolol
This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
Sponsors
Qilu Hospital of Shandong University
Study design
Observational model
CASE_CROSSOVER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Weeks to 54 Weeks
Healthy volunteers
No
Inclusion criteria
* IHs diagnosed by medical history and physical examination * no previous treatment with other medications
Exclusion criteria
* a history or risk of asthma, reactive airway disease, impaired renal or liver function, heart defects or arrhythmia, hypotension and hypersensitivity to propranolol * Infants who did not adhere to the treatments or attend follow-up visits * Infants with other known risk factors for developmental delay or growth restriction, such as prematurity, small for gestational age, or other major congenital malformations, were also excluded * No other treatment was used during the oral propranolol course
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change on the height of the patients | at the beginning of the treatment, at the end of treatment and 2 years after the treatment | we recorded the height of the patients in meters. |
| Change on the weight of the patients | at the beginning of the treatment, at the end of treatment and 2 years after the treatment | we recorded the weight of the patients in kilograms. |
Outcome results
None listed